Icon

COREG (nda020297)- (3.125MG,6.25MG,12.5MG,25MG)

CARVEDILOL WAYLIS THERAP
3.125MG,6.25MG,12.5MG,25MG
Yes No
2016-Aug-07 Expired
None None
None No
COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: • mild to severe chronic heart failure • left ventricular dysfunction following myocardial infarction in clinically stable patients • hypertension
13 0 9
Total Other Developers 20
Drugs with Suitability No
3.125MG ** ** - - 7
6.25MG ** ** - 8 -
12.5MG ** ** - - 8
25MG ** ** - - 8
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ******* ****** *****, *.*. *****, ******-********, *****, ******** ******* ******, ***** (***) ***
****** ******* ******* ******** ******* ******* *********** **** ** *-**/* & ***/*, ****, ********** ********* ****,, *****, *********** *** ***, ***** (***) ***
****** ****** ****** ******* ******* *********** **** **. *-*/* *** *-*, *** ********** **** ***** *****, ******* *****, **** ******, *********** ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** *-*, ******* ********** ******, *******-******,, ***, ** ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-*, **. **. ***/*, ***/*, ***/*, **** **. *-*/*, ***** ***, ***** ********** ****, ********* (*******), ********* (******), ************ (********), ************, ********* ******, ***** (***) ***
****** ******* *** ******* *************** ******* *********** ***, *********, *****, ******* ****, ********** (***) ***
****** ********* ****** ******** ****** ******* ******* *** *********** ****-**, ****** **. ** & **, ************* ******* ***- *********, ******** ******, **********, ********* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** **** ******* ****** ******* *********** **** **. **-**, ****** **, ******** ****, *********, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.